Schizophrenia is a serious mental illness, characterized by incoherent or illogical thoughts, bizarre behavior and speech, and delusions or hallucinations, such as hearing voices. Schizophrenia typically first presents in adolescence and young adulthood, and is associated with a prodromal period that can last for months or years, during which emotional, behavioral, and attenuated psychotic symptoms first appear.
Recent events and opinion
Recent events and opinion
- Johnson & Johnson’s LAI Invega franchise and Vraylar for negative symptoms will address unmet need and dominate the market.
- Survey shows slow adoption of newer drugs, as mature, oral antipsychotic monotherapies are the mainstay of treatment.
- Despite its proven individual and societal burden, recent schizophrenia epidemiological data are scarce.
- Broad-efficacy Vraylar is heralded as the future market leader targeting positive and negative symptoms.
- Pipeline drugs are expected to have little extra value over current antipsychotics, leading to limited market penetration.
Table of Contents
FORECAST: SCHIZOPHRENIA (Published on 19 March 2018)
- Overview
- Recent Forecast Updates
- Market Dynamics
- Forecast And Future Trends
- Market Definition And Methodology
- Primary Research Methodology
- Bibliography
- Product Profile (Late Stage): Alks 3831
- Product Profile: Abilify
- Product Profile: Abilify Maintena
- Product Profile: Aristada
- Product Profile: Invega Sustenna/Invega Trinza
- Product Profile: Latuda
- Product Profile: Lonasen
- Product Profile (Late Stage): Min-101
- Product Profile (Late Stage): Nuplazid
- Product Profile: Rexulti
- Product Profile: Risperdal Consta
- Product Profile: Saphris
- Product Profile: Seroquel/Seroquel Xr
- Product Profile: Vraylar
- Product Profile: Zyprexa
- Product Profile (Late Stage): Lumateperone
TREATMENT: SCHIZOPHRENIA (Published on 30 November 2017)
- Overview
- Executive Summary
- Primary Research Methodology
- Disease Definition And Diagnosis
- Patient Segmentation
- Current Treatment Options
- Treatment Dynamics
- Unmet Needs In Schizophrenia
EPIDEMIOLOGY: SCHIZOPHRENIA (Published on 31 July 2019)
- Overview
- Disease Background
- Methodology
- Forecast
- Bibliography
- Appendix: Additional Sources
MARKETED DRUGS: SCHIZOPHRENIA (Published on 19 March 2018)
- Overview
- Product Overview
- Product Profile: Abilify
- Product Profile: Abilify Maintena
- Product Profile: Aristada
- Product Profile: Invega Sustenna/Invega Trinza
- Product Profile: Latuda
- Product Profile: Lonasen
- Product Profile: Rexulti
- Product Profile: Risperdal Consta
- Product Profile: Saphris
- Product Profile: Seroquel/Seroquel Xr
- Product Profile: Vraylar
- Product Profile: Zyprexa
PIPELINE: SCHIZOPHRENIA (Published on 19 March 2018)
- Overview
- Clinical Pipeline Overview
- Additional Pharma Intelligence Pipeline Resources
- Product Profile (Late Stage): Alks 3831
- Product Profile (Late Stage): Lu Af35700
- Product Profile (Late Stage): Min-101
- Product Profile (Late Stage): Nuplazid
- Product Profile (Late Stage): Lumateperone
LIST OF FIGURES
Figure 1: Schizophrenia – current and future market dynamics analysis
Figure 2: The author's assessment summary of key marketed and pipeline drugs for schizophrenia
Figure 3: Schizophrenia market sales across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Growth dynamics of the schizophrenia market across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Atypical antipsychotic sales across the US, Japan, and five major EU markets, by formulation, 2017–26
Figure 6: Sales of top competing LAI brands for schizophrenia across the US, Japan, and five major EU markets, by brand, 2017–26
Figure 7: Sales of the highest-selling competing oral brands across the US, Japan, and five major EU markets, by brand, 2017–26
Figure 8: Methodology flow for The author's schizophrenia forecast
Figure 9: Price sources and calculations, by country
Figure 10: ALKS 3831 for schizophrenia – SWOT analysis
Figure 11: The author's drug assessment summary of ALKS 3831 for schizophrenia
Figure 12: The author's drug assessment summary of ALKS 3831 for schizophrenia
Figure 13: ALKS 3831 sales for schizophrenia in the US, 2017–26
Figure 14: Abilify for schizophrenia – SWOT analysis
Figure 15: The author's drug assessment summary of Abilify for schizophrenia
Figure 16: The author's drug assessment summary of Abilify for schizophrenia
Figure 17: Abilify sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 18: Abilify Maintena for schizophrenia – SWOT analysis
Figure 19: The author's drug assessment summary of Abilify Maintena for schizophrenia
Figure 20: The author's drug assessment summary of Abilify Maintena for schizophrenia
Figure 21: Abilify Maintena sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 22: Aristada for schizophrenia – SWOT analysis
Figure 23: The author's drug assessment summary of Aristada for schizophrenia
Figure 24: The author's drug assessment summary of Aristada for schizophrenia
Figure 25: Aristada sales for schizophrenia in the US, 2017–26
Figure 26: Invega Sustenna/Invega Trinza for schizophrenia – SWOT analysis
Figure 27: The author's drug assessment summary of Invega Sustenna/Invega Trinza for schizophrenia
Figure 28: The author's drug assessment summary of Invega Sustenna/Invega Trinza for schizophrenia
Figure 29: Invega Sustenna sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 30: Invega Trinza sales for schizophrenia across the US and five major EU markets, by country, 2017–26
Figure 31: Latuda for schizophrenia – SWOT analysis
Figure 32: The author's drug assessment summary of Latuda for schizophrenia
Figure 33: The author's drug assessment summary of Latuda for schizophrenia
Figure 34: Latuda sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country, 2017–26
Figure 35: Lonasen for schizophrenia – SWOT analysis
Figure 36: The author's drug assessment summary of Lonasen for schizophrenia
Figure 37: The author's drug assessment summary of Lonasen for schizophrenia
Figure 38: Lonasen sales for schizophrenia in Japan, 2017–26
Figure 39: MIN-101 for schizophrenia – SWOT analysis
Figure 40: The author's drug assessment summary of MIN-101 for schizophrenia
Figure 41: The author's drug assessment summary of MIN-101 for schizophrenia
Figure 42: MIN-101 sales for schizophrenia in the US, 2017–26
Figure 43: Nuplazid for schizophrenia – SWOT analysis
Figure 44: The author's drug assessment summary of Nuplazid for schizophrenia
Figure 45: The author's drug assessment summary of Nuplazid for schizophrenia
Figure 46: Nuplazid sales for schizophrenia across the US and five major EU markets, by country, 2017–26
Figure 47: Rexulti for schizophrenia – SWOT analysis
Figure 48: The author's drug assessment summary of Rexulti for schizophrenia
Figure 49: The author's drug assessment summary of Rexulti for schizophrenia
Figure 50: Rexulti sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 51: Risperdal Consta for schizophrenia – SWOT analysis
Figure 52: The author's drug assessment summary of Risperdal Consta for schizophrenia
Figure 53: The author's drug assessment summary of Risperdal Consta for schizophrenia
Figure 54: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 55: Saphris for schizophrenia – SWOT analysis
Figure 56: The author's drug assessment summary of Saphris for schizophrenia
Figure 57: The author's drug assessment summary of Saphris for schizophrenia
Figure 58: Saphris sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country, 2017–26
Figure 59: Seroquel/Seroquel XR for schizophrenia – SWOT analysis
Figure 60: The author's drug assessment summary of Seroquel/Seroquel XR for schizophrenia
Figure 61: The author's drug assessment summary of Seroquel/Seroquel XR for schizophrenia
Figure 62: Seroquel/Seroquel XR sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 63: Vraylar for schizophrenia – SWOT analysis
Figure 64: The author's drug assessment summary of Vraylar for schizophrenia
Figure 65: The author's drug assessment summary of Vraylar for schizophrenia
Figure 66: Vraylar sales for schizophrenia across the US and five major EU markets, by country, 2017–26
Figure 67: Zyprexa for schizophrenia – SWOT analysis
Figure 68: The author's drug assessment summary of Zyprexa for schizophrenia
Figure 69: The author's drug assessment summary of Zyprexa for schizophrenia
Figure 70: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 71: Lumateperone for schizophrenia – SWOT analysis
Figure 72: The author's drug assessment summary of lumateperone for schizophrenia
Figure 73: The author's drug assessment summary of lumateperone for schizophrenia
Figure 74: Lumateperone sales for schizophrenia in the US, 2017–26
Figure 75: Symptoms of schizophrenia
Figure 76: Prevalence of schizophrenia symptoms in the US, Japan, and five major EU markets, by country
Figure 77: An integrative framework for investigating the role of environmentally shaped immune mechanisms in psychosis spectrum disorders
Figure 78: DSM-V diagnostic criteria (A–C)
Figure 79: Diagnosis rates for schizophrenia in the US, Japan, and five major EU markets, by country
Figure 80: Timeline of schizophrenia disease phases
Figure 81: Segmentation of schizophrenia patients by disease phase in the US, Japan, and five major EU markets, by country
Figure 82: Segmentation of schizophrenia patients by line of therapy across the US, Japan, and five major EU markets
Figure 83: Drug treatment rate for schizophrenia in the US, Japan, and five major EU markets, by country
Figure 84: Schizophrenia treatment guideline recommendations by disease phase
Figure 85: Top five overall regimens by formulation across the US, Japan, and five major EU markets, by schizophrenia disease phase and line of therapy
Figure 86: Top five overall drug treatments across the US, Japan, and five major EU markets, by schizophrenia disease phase and line of therapy
Figure 87: Top five first-line drug treatments for acute phase schizophrenia in the US, Japan, and five major EU markets, by country
Figure 88: Top five second-line and beyond drug treatments for acute phase schizophrenia in the US, Japan, and five major EU markets, by country
Figure 89: Top five first-line drug treatments for stable phase schizophrenia in the US, Japan, and five major EU markets, by country
Figure 90: Top five second-line and beyond drug treatments for stable phase schizophrenia in the US, Japan, and five major EU markets, by country
Figure 91: Compliance rates of schizophrenia patients in the US, Japan, and five major EU markets, by country and disease phase
Figure 92: Reasons for nonadherence in serious mental illness
Figure 93: Key unmet needs for schizophrenia, 2017
Figure 94: Advantages and disadvantages of long-acting injectable antipsychotics
Figure 95: Trends in 12-month prevalent cases of schizophrenia in the US, Japan, and five major EU markets, by country, 2018–38
Figure 96: Abilify for schizophrenia – SWOT analysis
Figure 97: The author's drug assessment summary of Abilify for schizophrenia
Figure 98: The author's drug assessment summary of Abilify for schizophrenia
Figure 99: Abilify sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 100: Abilify Maintena for schizophrenia – SWOT analysis
Figure 101: The author's drug assessment summary of Abilify Maintena for schizophrenia
Figure 102: The author's drug assessment summary of Abilify Maintena for schizophrenia
Figure 103: Abilify Maintena sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 104: Aristada for schizophrenia – SWOT analysis
Figure 105: The author's drug assessment summary of Aristada for schizophrenia
Figure 106: The author's drug assessment summary of Aristada for schizophrenia
Figure 107: Aristada sales for schizophrenia in the US, 2017–26
Figure 108: Invega Sustenna/Invega Trinza for schizophrenia – SWOT analysis
Figure 109: The author's drug assessment summary of Invega Sustenna/Invega Trinza for schizophrenia
Figure 110: The author's drug assessment summary of Invega Sustenna/Invega Trinza for schizophrenia
Figure 111: Invega Sustenna sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 112: Invega Trinza sales for schizophrenia across the US and five major EU markets, by country, 2017–26
Figure 113: Latuda for schizophrenia – SWOT analysis
Figure 114: The author's drug assessment summary of Latuda for schizophrenia
Figure 115: The author's drug assessment summary of Latuda for schizophrenia
Figure 116: Latuda sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country, 2017–26
Figure 117: Lonasen for schizophrenia – SWOT analysis
Figure 118: The author's drug assessment summary of Lonasen for schizophrenia
Figure 119: The author's drug assessment summary of Lonasen for schizophrenia
Figure 120: Lonasen sales for schizophrenia in Japan, 2017–26
Figure 121: Rexulti for schizophrenia – SWOT analysis
Figure 122: The author's drug assessment summary of Rexulti for schizophrenia
Figure 123: The author's drug assessment summary of Rexulti for schizophrenia
Figure 124: Rexulti sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 125: Risperdal Consta for schizophrenia – SWOT analysis
Figure 126: The author's drug assessment summary of Risperdal Consta for schizophrenia
Figure 127: The author's drug assessment summary of Risperdal Consta for schizophrenia
Figure 128: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 129: Saphris for schizophrenia – SWOT analysis
Figure 130: The author's drug assessment summary of Saphris for schizophrenia
Figure 131: The author's drug assessment summary of Saphris for schizophrenia
Figure 132: Saphris sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country, 2017–26
Figure 133: Seroquel/Seroquel XR for schizophrenia – SWOT analysis
Figure 134: The author's drug assessment summary of Seroquel/Seroquel XR for schizophrenia
Figure 135: The author's drug assessment summary of Seroquel/Seroquel XR for schizophrenia
Figure 136: Seroquel/Seroquel XR sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 137: Vraylar for schizophrenia – SWOT analysis
Figure 138: The author's drug assessment summary of Vraylar for schizophrenia
Figure 139: The author's drug assessment summary of Vraylar for schizophrenia
Figure 140: Vraylar sales for schizophrenia across the US and five major EU markets, by country, 2017–26
Figure 141: Zyprexa for schizophrenia – SWOT analysis
Figure 142: The author's drug assessment summary of Zyprexa for schizophrenia
Figure 143: The author's drug assessment summary of Zyprexa for schizophrenia
Figure 144: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 145: ALKS 3831 for schizophrenia – SWOT analysis
Figure 146: The author's drug assessment summary of ALKS 3831 for schizophrenia
Figure 147: The author's drug assessment summary of ALKS 3831 for schizophrenia
Figure 148: ALKS 3831 sales for schizophrenia in the US, 2017–26
Figure 149: Lu AF35700 for schizophrenia – SWOT analysis
Figure 150: MIN-101 for schizophrenia – SWOT analysis
Figure 151: The author's drug assessment summary of MIN-101 for schizophrenia
Figure 152: The author's drug assessment summary of MIN-101 for schizophrenia
Figure 153: MIN-101 sales for schizophrenia in the US, 2017–26
Figure 154: Nuplazid for schizophrenia – SWOT analysis
Figure 155: The author's drug assessment summary of Nuplazid for schizophrenia
Figure 156: The author's drug assessment summary of Nuplazid for schizophrenia
Figure 157: Nuplazid sales for schizophrenia across the US and five major EU markets, by country, 2017–26
Figure 158: Lumateperone for schizophrenia – SWOT analysis
Figure 159: The author's drug assessment summary of lumateperone for schizophrenia
Figure 160: The author's drug assessment summary of lumateperone for schizophrenia
Figure 161: Lumateperone sales for schizophrenia in the US, 2017–26
Figure 2: The author's assessment summary of key marketed and pipeline drugs for schizophrenia
Figure 3: Schizophrenia market sales across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Growth dynamics of the schizophrenia market across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Atypical antipsychotic sales across the US, Japan, and five major EU markets, by formulation, 2017–26
Figure 6: Sales of top competing LAI brands for schizophrenia across the US, Japan, and five major EU markets, by brand, 2017–26
Figure 7: Sales of the highest-selling competing oral brands across the US, Japan, and five major EU markets, by brand, 2017–26
Figure 8: Methodology flow for The author's schizophrenia forecast
Figure 9: Price sources and calculations, by country
Figure 10: ALKS 3831 for schizophrenia – SWOT analysis
Figure 11: The author's drug assessment summary of ALKS 3831 for schizophrenia
Figure 12: The author's drug assessment summary of ALKS 3831 for schizophrenia
Figure 13: ALKS 3831 sales for schizophrenia in the US, 2017–26
Figure 14: Abilify for schizophrenia – SWOT analysis
Figure 15: The author's drug assessment summary of Abilify for schizophrenia
Figure 16: The author's drug assessment summary of Abilify for schizophrenia
Figure 17: Abilify sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 18: Abilify Maintena for schizophrenia – SWOT analysis
Figure 19: The author's drug assessment summary of Abilify Maintena for schizophrenia
Figure 20: The author's drug assessment summary of Abilify Maintena for schizophrenia
Figure 21: Abilify Maintena sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 22: Aristada for schizophrenia – SWOT analysis
Figure 23: The author's drug assessment summary of Aristada for schizophrenia
Figure 24: The author's drug assessment summary of Aristada for schizophrenia
Figure 25: Aristada sales for schizophrenia in the US, 2017–26
Figure 26: Invega Sustenna/Invega Trinza for schizophrenia – SWOT analysis
Figure 27: The author's drug assessment summary of Invega Sustenna/Invega Trinza for schizophrenia
Figure 28: The author's drug assessment summary of Invega Sustenna/Invega Trinza for schizophrenia
Figure 29: Invega Sustenna sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 30: Invega Trinza sales for schizophrenia across the US and five major EU markets, by country, 2017–26
Figure 31: Latuda for schizophrenia – SWOT analysis
Figure 32: The author's drug assessment summary of Latuda for schizophrenia
Figure 33: The author's drug assessment summary of Latuda for schizophrenia
Figure 34: Latuda sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country, 2017–26
Figure 35: Lonasen for schizophrenia – SWOT analysis
Figure 36: The author's drug assessment summary of Lonasen for schizophrenia
Figure 37: The author's drug assessment summary of Lonasen for schizophrenia
Figure 38: Lonasen sales for schizophrenia in Japan, 2017–26
Figure 39: MIN-101 for schizophrenia – SWOT analysis
Figure 40: The author's drug assessment summary of MIN-101 for schizophrenia
Figure 41: The author's drug assessment summary of MIN-101 for schizophrenia
Figure 42: MIN-101 sales for schizophrenia in the US, 2017–26
Figure 43: Nuplazid for schizophrenia – SWOT analysis
Figure 44: The author's drug assessment summary of Nuplazid for schizophrenia
Figure 45: The author's drug assessment summary of Nuplazid for schizophrenia
Figure 46: Nuplazid sales for schizophrenia across the US and five major EU markets, by country, 2017–26
Figure 47: Rexulti for schizophrenia – SWOT analysis
Figure 48: The author's drug assessment summary of Rexulti for schizophrenia
Figure 49: The author's drug assessment summary of Rexulti for schizophrenia
Figure 50: Rexulti sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 51: Risperdal Consta for schizophrenia – SWOT analysis
Figure 52: The author's drug assessment summary of Risperdal Consta for schizophrenia
Figure 53: The author's drug assessment summary of Risperdal Consta for schizophrenia
Figure 54: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 55: Saphris for schizophrenia – SWOT analysis
Figure 56: The author's drug assessment summary of Saphris for schizophrenia
Figure 57: The author's drug assessment summary of Saphris for schizophrenia
Figure 58: Saphris sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country, 2017–26
Figure 59: Seroquel/Seroquel XR for schizophrenia – SWOT analysis
Figure 60: The author's drug assessment summary of Seroquel/Seroquel XR for schizophrenia
Figure 61: The author's drug assessment summary of Seroquel/Seroquel XR for schizophrenia
Figure 62: Seroquel/Seroquel XR sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 63: Vraylar for schizophrenia – SWOT analysis
Figure 64: The author's drug assessment summary of Vraylar for schizophrenia
Figure 65: The author's drug assessment summary of Vraylar for schizophrenia
Figure 66: Vraylar sales for schizophrenia across the US and five major EU markets, by country, 2017–26
Figure 67: Zyprexa for schizophrenia – SWOT analysis
Figure 68: The author's drug assessment summary of Zyprexa for schizophrenia
Figure 69: The author's drug assessment summary of Zyprexa for schizophrenia
Figure 70: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 71: Lumateperone for schizophrenia – SWOT analysis
Figure 72: The author's drug assessment summary of lumateperone for schizophrenia
Figure 73: The author's drug assessment summary of lumateperone for schizophrenia
Figure 74: Lumateperone sales for schizophrenia in the US, 2017–26
Figure 75: Symptoms of schizophrenia
Figure 76: Prevalence of schizophrenia symptoms in the US, Japan, and five major EU markets, by country
Figure 77: An integrative framework for investigating the role of environmentally shaped immune mechanisms in psychosis spectrum disorders
Figure 78: DSM-V diagnostic criteria (A–C)
Figure 79: Diagnosis rates for schizophrenia in the US, Japan, and five major EU markets, by country
Figure 80: Timeline of schizophrenia disease phases
Figure 81: Segmentation of schizophrenia patients by disease phase in the US, Japan, and five major EU markets, by country
Figure 82: Segmentation of schizophrenia patients by line of therapy across the US, Japan, and five major EU markets
Figure 83: Drug treatment rate for schizophrenia in the US, Japan, and five major EU markets, by country
Figure 84: Schizophrenia treatment guideline recommendations by disease phase
Figure 85: Top five overall regimens by formulation across the US, Japan, and five major EU markets, by schizophrenia disease phase and line of therapy
Figure 86: Top five overall drug treatments across the US, Japan, and five major EU markets, by schizophrenia disease phase and line of therapy
Figure 87: Top five first-line drug treatments for acute phase schizophrenia in the US, Japan, and five major EU markets, by country
Figure 88: Top five second-line and beyond drug treatments for acute phase schizophrenia in the US, Japan, and five major EU markets, by country
Figure 89: Top five first-line drug treatments for stable phase schizophrenia in the US, Japan, and five major EU markets, by country
Figure 90: Top five second-line and beyond drug treatments for stable phase schizophrenia in the US, Japan, and five major EU markets, by country
Figure 91: Compliance rates of schizophrenia patients in the US, Japan, and five major EU markets, by country and disease phase
Figure 92: Reasons for nonadherence in serious mental illness
Figure 93: Key unmet needs for schizophrenia, 2017
Figure 94: Advantages and disadvantages of long-acting injectable antipsychotics
Figure 95: Trends in 12-month prevalent cases of schizophrenia in the US, Japan, and five major EU markets, by country, 2018–38
Figure 96: Abilify for schizophrenia – SWOT analysis
Figure 97: The author's drug assessment summary of Abilify for schizophrenia
Figure 98: The author's drug assessment summary of Abilify for schizophrenia
Figure 99: Abilify sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 100: Abilify Maintena for schizophrenia – SWOT analysis
Figure 101: The author's drug assessment summary of Abilify Maintena for schizophrenia
Figure 102: The author's drug assessment summary of Abilify Maintena for schizophrenia
Figure 103: Abilify Maintena sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 104: Aristada for schizophrenia – SWOT analysis
Figure 105: The author's drug assessment summary of Aristada for schizophrenia
Figure 106: The author's drug assessment summary of Aristada for schizophrenia
Figure 107: Aristada sales for schizophrenia in the US, 2017–26
Figure 108: Invega Sustenna/Invega Trinza for schizophrenia – SWOT analysis
Figure 109: The author's drug assessment summary of Invega Sustenna/Invega Trinza for schizophrenia
Figure 110: The author's drug assessment summary of Invega Sustenna/Invega Trinza for schizophrenia
Figure 111: Invega Sustenna sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 112: Invega Trinza sales for schizophrenia across the US and five major EU markets, by country, 2017–26
Figure 113: Latuda for schizophrenia – SWOT analysis
Figure 114: The author's drug assessment summary of Latuda for schizophrenia
Figure 115: The author's drug assessment summary of Latuda for schizophrenia
Figure 116: Latuda sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country, 2017–26
Figure 117: Lonasen for schizophrenia – SWOT analysis
Figure 118: The author's drug assessment summary of Lonasen for schizophrenia
Figure 119: The author's drug assessment summary of Lonasen for schizophrenia
Figure 120: Lonasen sales for schizophrenia in Japan, 2017–26
Figure 121: Rexulti for schizophrenia – SWOT analysis
Figure 122: The author's drug assessment summary of Rexulti for schizophrenia
Figure 123: The author's drug assessment summary of Rexulti for schizophrenia
Figure 124: Rexulti sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 125: Risperdal Consta for schizophrenia – SWOT analysis
Figure 126: The author's drug assessment summary of Risperdal Consta for schizophrenia
Figure 127: The author's drug assessment summary of Risperdal Consta for schizophrenia
Figure 128: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 129: Saphris for schizophrenia – SWOT analysis
Figure 130: The author's drug assessment summary of Saphris for schizophrenia
Figure 131: The author's drug assessment summary of Saphris for schizophrenia
Figure 132: Saphris sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country, 2017–26
Figure 133: Seroquel/Seroquel XR for schizophrenia – SWOT analysis
Figure 134: The author's drug assessment summary of Seroquel/Seroquel XR for schizophrenia
Figure 135: The author's drug assessment summary of Seroquel/Seroquel XR for schizophrenia
Figure 136: Seroquel/Seroquel XR sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 137: Vraylar for schizophrenia – SWOT analysis
Figure 138: The author's drug assessment summary of Vraylar for schizophrenia
Figure 139: The author's drug assessment summary of Vraylar for schizophrenia
Figure 140: Vraylar sales for schizophrenia across the US and five major EU markets, by country, 2017–26
Figure 141: Zyprexa for schizophrenia – SWOT analysis
Figure 142: The author's drug assessment summary of Zyprexa for schizophrenia
Figure 143: The author's drug assessment summary of Zyprexa for schizophrenia
Figure 144: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
Figure 145: ALKS 3831 for schizophrenia – SWOT analysis
Figure 146: The author's drug assessment summary of ALKS 3831 for schizophrenia
Figure 147: The author's drug assessment summary of ALKS 3831 for schizophrenia
Figure 148: ALKS 3831 sales for schizophrenia in the US, 2017–26
Figure 149: Lu AF35700 for schizophrenia – SWOT analysis
Figure 150: MIN-101 for schizophrenia – SWOT analysis
Figure 151: The author's drug assessment summary of MIN-101 for schizophrenia
Figure 152: The author's drug assessment summary of MIN-101 for schizophrenia
Figure 153: MIN-101 sales for schizophrenia in the US, 2017–26
Figure 154: Nuplazid for schizophrenia – SWOT analysis
Figure 155: The author's drug assessment summary of Nuplazid for schizophrenia
Figure 156: The author's drug assessment summary of Nuplazid for schizophrenia
Figure 157: Nuplazid sales for schizophrenia across the US and five major EU markets, by country, 2017–26
Figure 158: Lumateperone for schizophrenia – SWOT analysis
Figure 159: The author's drug assessment summary of lumateperone for schizophrenia
Figure 160: The author's drug assessment summary of lumateperone for schizophrenia
Figure 161: Lumateperone sales for schizophrenia in the US, 2017–26
LIST OF TABLES
Table 1: Schizophrenia market sales across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 2: Atypical antipsychotic sales across the US, Japan, and five major EU markets, by formulation ($m), 2017–26
Table 3: Sales of the top four LAIs for schizophrenia across the US, Japan, and five major EU markets, 2017–26
Table 4: Sales of top competing LAI brands for schizophrenia across the US, Japan, and five major EU markets, by brand ($m), 2017–26
Table 5: Sales of the highest-selling competing oral brands across the US, Japan, and five major EU markets, by brand ($m), 2017–26
Table 6: Exchange rates used for calculating prices
Table 7: Psychiatrists surveyed for the schizophrenia primary research study, 2017
Table 8: ALKS 3831 drug profile
Table 9: ALKS 3831 Phase III data in schizophrenia
Table 10: ALKS 3831 Phase III trials in schizophrenia
Table 11: ALKS 3831 sales for schizophrenia in the US ($m), 2017–26
Table 12: Abilify drug profile
Table 13: Abilify pivotal trial data in schizophrenia
Table 14: Abilify sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 15: Abilify Maintena drug profile
Table 16: Abilify Maintena pivotal trial data in schizophrenia
Table 17: Abilify Maintena other late-phase clinical data in schizophrenia
Table 18: Abilify Maintena sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 19: Aristada drug profile
Table 20: Aristada pivotal trial data in schizophrenia
Table 21: Aristada other late-phase trial data in schizophrenia
Table 22: Aristada ongoing trial in schizophrenia
Table 23: Aristada sales for schizophrenia in the US ($m), 2017–26
Table 24: Invega Sustenna/Invega Trinza drug profile
Table 25: Invega Sustenna pivotal trial data in schizophrenia
Table 26: Invega Trinza pivotal trial data in schizophrenia
Table 27: Invega Sustenna sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 28: Invega Trinza sales for schizophrenia across the US and five major EU markets, by country ($m), 2017–26
Table 29: Latuda drug profile
Table 30: Latuda pivotal trial data in schizophrenia
Table 31: Latuda other late-phase trial data in schizophrenia
Table 32: Latuda sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country ($m), 2017–26
Table 33: Lonasen drug profile
Table 34: Lonasen pivotal trial data in schizophrenia
Table 35: Lonasen transdermal patch trial data in schizophrenia
Table 36: Lonasen ongoing trials in schizophrenia
Table 37: Lonasen sales for schizophrenia in Japan ($m), 2017–26
Table 38: MIN-101 drug profile
Table 39: MIN-101 planned Phase III trial in schizophrenia
Table 40: MIN-101 Phase IIb trial data in schizophrenia
Table 41: MIN-101 sales for schizophrenia in the US ($m), 2017–26
Table 42: Nuplazid drug profile
Table 43: Nuplazid Phase II and Phase III trials in schizophrenia
Table 44: Nuplazid Phase II data in schizophrenia
Table 45: Nuplazid sales for schizophrenia across the US and five major EU markets, by country ($m), 2017–26
Table 46: Rexulti drug profile
Table 47: Rexulti pivotal trial data in schizophrenia
Table 48: Rexulti sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 49: Risperdal Consta drug profile
Table 50: Risperdal Consta pivotal trial data in schizophrenia
Table 51: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 52: Saphris drug profile
Table 53: Saphris pivotal trial data in schizophrenia
Table 54: Saphris sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country ($m), 2017–26
Table 55: Seroquel/Seroquel XR drug profile
Table 56: Seroquel/Seroquel XR pivotal trial data in schizophrenia
Table 57: Seroquel/Seroquel XR sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 58: Vraylar drug profile
Table 59: Vraylar pivotal trial data in schizophrenia
Table 60: Vraylar other late-phase trial data in schizophrenia
Table 61: Vraylar sales for schizophrenia across the US and five major EU markets, by country ($m), 2017–26
Table 62: Zyprexa drug profile
Table 63: Zyprexa pivotal trial data in schizophrenia
Table 64: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 65: Lumateperone drug profile
Table 66: Lumateperone Phase II and Phase III data in schizophrenia
Table 67: Lumateperone other interim Phase II data in schizophrenia
Table 68: Lumateperone sales for schizophrenia in the US ($m), 2017–26
Table 69: Physicians surveyed for the schizophrenia primary research study, 2017
Table 70: Prevalence of schizophrenia symptoms in the US, Japan, and five major EU markets (%), by country
Table 71: Diagnosis rates for schizophrenia in the US, Japan, and five major EU markets (%), by country
Table 72: Segmentation of schizophrenia patients by disease phase in the US, Japan, and five major EU markets (%), by country
Table 73: Segmentation of schizophrenia patients by disease phase and line of therapy in the US, Japan, and five major EU markets (%), by country
Table 74: Drug treatment rate for schizophrenia in the US, Japan, and five major EU markets (%), by country and disease phase
Table 75: Leading therapies for schizophrenia
Table 76: Regimens by formulation according to patient share across the US, Japan, and five major EU markets (%), by schizophrenia disease phase and line of therapy
Table 77: Leading drug treatments according to patient share across the US, Japan, and five major EU markets (%), by schizophrenia disease phase and line of therapy
Table 78: Monotherapy and combination therapy use of oral olanzapine across the US, Japan, and 5EU (%), by schizophrenia disease phase and line of therapy
Table 79: Monotherapy and combination therapy use of oral aripiprazole across the US, Japan, and 5EU (%), by schizophrenia disease phase and line of therapy
Table 80: First-line drug treatments for acute phase schizophrenia in the US, Japan, and five major EU markets (%), by country
Table 81: Second-line and beyond drug treatments for acute phase schizophrenia in the US, Japan, and five major EU markets (%), by country
Table 82: First-line drug treatments for stable phase schizophrenia in the US, Japan, and five major EU markets (%), by country
Table 83: Second-line and beyond drug treatments for stable phase schizophrenia in the US, Japan, and five major EU markets (%), by country
Table 84: Compliance rates of schizophrenia patients in the US, Japan, and five major EU markets (%), by country and disease phase
Table 85: 12-month prevalent cases of schizophrenia in the US, Japan, and five major EU markets, by country, 2018–38
Table 86: Profiled key marketed drugs for schizophrenia
Table 87: Abilify drug profile
Table 88: Abilify pivotal trial data in schizophrenia
Table 89: Abilify sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 90: Abilify Maintena drug profile
Table 91: Abilify Maintena pivotal trial data in schizophrenia
Table 92: Abilify Maintena other late-phase clinical data in schizophrenia
Table 93: Abilify Maintena sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 94: Aristada drug profile
Table 95: Aristada pivotal trial data in schizophrenia
Table 96: Aristada other late-phase trial data in schizophrenia
Table 97: Aristada ongoing trial in schizophrenia
Table 98: Aristada sales for schizophrenia in the US ($m), 2017–26
Table 99: Invega Sustenna/Invega Trinza drug profile
Table 100: Invega Sustenna pivotal trial data in schizophrenia
Table 101: Invega Trinza pivotal trial data in schizophrenia
Table 102: Invega Sustenna sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 103: Invega Trinza sales for schizophrenia across the US and five major EU markets, by country ($m), 2017–26
Table 104: Latuda drug profile
Table 105: Latuda pivotal trial data in schizophrenia
Table 106: Latuda other late-phase trial data in schizophrenia
Table 107: Latuda sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country ($m), 2017–26
Table 108: Lonasen drug profile
Table 109: Lonasen pivotal trial data in schizophrenia
Table 110: Lonasen transdermal patch trial data in schizophrenia
Table 111: Lonasen ongoing trials in schizophrenia
Table 112: Lonasen sales for schizophrenia in Japan ($m), 2017–26
Table 113: Rexulti drug profile
Table 114: Rexulti pivotal trial data in schizophrenia
Table 115: Rexulti sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 116: Risperdal Consta drug profile
Table 117: Risperdal Consta pivotal trial data in schizophrenia
Table 118: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 119: Saphris drug profile
Table 120: Saphris pivotal trial data in schizophrenia
Table 121: Saphris sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country ($m), 2017–26
Table 122: Seroquel/Seroquel XR drug profile
Table 123: Seroquel/Seroquel XR pivotal trial data in schizophrenia
Table 124: Seroquel/Seroquel XR sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 125: Vraylar drug profile
Table 126: Vraylar pivotal trial data in schizophrenia
Table 127: Vraylar other late-phase trial data in schizophrenia
Table 128: Vraylar sales for schizophrenia across the US and five major EU markets, by country ($m), 2017–26
Table 129: Zyprexa drug profile
Table 130: Zyprexa pivotal trial data in schizophrenia
Table 131: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 132: Profiled pipeline products in development for schizophrenia
Table 133: ALKS 3831 drug profile
Table 134: ALKS 3831 Phase III data in schizophrenia
Table 135: ALKS 3831 Phase III trials in schizophrenia
Table 136: ALKS 3831 sales for schizophrenia in the US ($m), 2017–26
Table 137: Lu AF35700 drug profile
Table 138: Lu AF35700 Phase II and Phase III trials in schizophrenia
Table 139: MIN-101 drug profile
Table 140: MIN-101 planned Phase III trial in schizophrenia
Table 141: MIN-101 Phase IIb trial data in schizophrenia
Table 142: MIN-101 sales for schizophrenia in the US ($m), 2017–26
Table 143: Nuplazid drug profile
Table 144: Nuplazid Phase II and Phase III trials in schizophrenia
Table 145: Nuplazid Phase II data in schizophrenia
Table 146: Nuplazid sales for schizophrenia across the US and five major EU markets, by country ($m), 2017–26
Table 147: Lumateperone drug profile
Table 148: Lumateperone Phase II and Phase III data in schizophrenia
Table 149: Lumateperone other interim Phase II data in schizophrenia
Table 150: Lumateperone sales for schizophrenia in the US ($m), 2017–26
Table 2: Atypical antipsychotic sales across the US, Japan, and five major EU markets, by formulation ($m), 2017–26
Table 3: Sales of the top four LAIs for schizophrenia across the US, Japan, and five major EU markets, 2017–26
Table 4: Sales of top competing LAI brands for schizophrenia across the US, Japan, and five major EU markets, by brand ($m), 2017–26
Table 5: Sales of the highest-selling competing oral brands across the US, Japan, and five major EU markets, by brand ($m), 2017–26
Table 6: Exchange rates used for calculating prices
Table 7: Psychiatrists surveyed for the schizophrenia primary research study, 2017
Table 8: ALKS 3831 drug profile
Table 9: ALKS 3831 Phase III data in schizophrenia
Table 10: ALKS 3831 Phase III trials in schizophrenia
Table 11: ALKS 3831 sales for schizophrenia in the US ($m), 2017–26
Table 12: Abilify drug profile
Table 13: Abilify pivotal trial data in schizophrenia
Table 14: Abilify sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 15: Abilify Maintena drug profile
Table 16: Abilify Maintena pivotal trial data in schizophrenia
Table 17: Abilify Maintena other late-phase clinical data in schizophrenia
Table 18: Abilify Maintena sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 19: Aristada drug profile
Table 20: Aristada pivotal trial data in schizophrenia
Table 21: Aristada other late-phase trial data in schizophrenia
Table 22: Aristada ongoing trial in schizophrenia
Table 23: Aristada sales for schizophrenia in the US ($m), 2017–26
Table 24: Invega Sustenna/Invega Trinza drug profile
Table 25: Invega Sustenna pivotal trial data in schizophrenia
Table 26: Invega Trinza pivotal trial data in schizophrenia
Table 27: Invega Sustenna sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 28: Invega Trinza sales for schizophrenia across the US and five major EU markets, by country ($m), 2017–26
Table 29: Latuda drug profile
Table 30: Latuda pivotal trial data in schizophrenia
Table 31: Latuda other late-phase trial data in schizophrenia
Table 32: Latuda sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country ($m), 2017–26
Table 33: Lonasen drug profile
Table 34: Lonasen pivotal trial data in schizophrenia
Table 35: Lonasen transdermal patch trial data in schizophrenia
Table 36: Lonasen ongoing trials in schizophrenia
Table 37: Lonasen sales for schizophrenia in Japan ($m), 2017–26
Table 38: MIN-101 drug profile
Table 39: MIN-101 planned Phase III trial in schizophrenia
Table 40: MIN-101 Phase IIb trial data in schizophrenia
Table 41: MIN-101 sales for schizophrenia in the US ($m), 2017–26
Table 42: Nuplazid drug profile
Table 43: Nuplazid Phase II and Phase III trials in schizophrenia
Table 44: Nuplazid Phase II data in schizophrenia
Table 45: Nuplazid sales for schizophrenia across the US and five major EU markets, by country ($m), 2017–26
Table 46: Rexulti drug profile
Table 47: Rexulti pivotal trial data in schizophrenia
Table 48: Rexulti sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 49: Risperdal Consta drug profile
Table 50: Risperdal Consta pivotal trial data in schizophrenia
Table 51: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 52: Saphris drug profile
Table 53: Saphris pivotal trial data in schizophrenia
Table 54: Saphris sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country ($m), 2017–26
Table 55: Seroquel/Seroquel XR drug profile
Table 56: Seroquel/Seroquel XR pivotal trial data in schizophrenia
Table 57: Seroquel/Seroquel XR sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 58: Vraylar drug profile
Table 59: Vraylar pivotal trial data in schizophrenia
Table 60: Vraylar other late-phase trial data in schizophrenia
Table 61: Vraylar sales for schizophrenia across the US and five major EU markets, by country ($m), 2017–26
Table 62: Zyprexa drug profile
Table 63: Zyprexa pivotal trial data in schizophrenia
Table 64: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 65: Lumateperone drug profile
Table 66: Lumateperone Phase II and Phase III data in schizophrenia
Table 67: Lumateperone other interim Phase II data in schizophrenia
Table 68: Lumateperone sales for schizophrenia in the US ($m), 2017–26
Table 69: Physicians surveyed for the schizophrenia primary research study, 2017
Table 70: Prevalence of schizophrenia symptoms in the US, Japan, and five major EU markets (%), by country
Table 71: Diagnosis rates for schizophrenia in the US, Japan, and five major EU markets (%), by country
Table 72: Segmentation of schizophrenia patients by disease phase in the US, Japan, and five major EU markets (%), by country
Table 73: Segmentation of schizophrenia patients by disease phase and line of therapy in the US, Japan, and five major EU markets (%), by country
Table 74: Drug treatment rate for schizophrenia in the US, Japan, and five major EU markets (%), by country and disease phase
Table 75: Leading therapies for schizophrenia
Table 76: Regimens by formulation according to patient share across the US, Japan, and five major EU markets (%), by schizophrenia disease phase and line of therapy
Table 77: Leading drug treatments according to patient share across the US, Japan, and five major EU markets (%), by schizophrenia disease phase and line of therapy
Table 78: Monotherapy and combination therapy use of oral olanzapine across the US, Japan, and 5EU (%), by schizophrenia disease phase and line of therapy
Table 79: Monotherapy and combination therapy use of oral aripiprazole across the US, Japan, and 5EU (%), by schizophrenia disease phase and line of therapy
Table 80: First-line drug treatments for acute phase schizophrenia in the US, Japan, and five major EU markets (%), by country
Table 81: Second-line and beyond drug treatments for acute phase schizophrenia in the US, Japan, and five major EU markets (%), by country
Table 82: First-line drug treatments for stable phase schizophrenia in the US, Japan, and five major EU markets (%), by country
Table 83: Second-line and beyond drug treatments for stable phase schizophrenia in the US, Japan, and five major EU markets (%), by country
Table 84: Compliance rates of schizophrenia patients in the US, Japan, and five major EU markets (%), by country and disease phase
Table 85: 12-month prevalent cases of schizophrenia in the US, Japan, and five major EU markets, by country, 2018–38
Table 86: Profiled key marketed drugs for schizophrenia
Table 87: Abilify drug profile
Table 88: Abilify pivotal trial data in schizophrenia
Table 89: Abilify sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 90: Abilify Maintena drug profile
Table 91: Abilify Maintena pivotal trial data in schizophrenia
Table 92: Abilify Maintena other late-phase clinical data in schizophrenia
Table 93: Abilify Maintena sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 94: Aristada drug profile
Table 95: Aristada pivotal trial data in schizophrenia
Table 96: Aristada other late-phase trial data in schizophrenia
Table 97: Aristada ongoing trial in schizophrenia
Table 98: Aristada sales for schizophrenia in the US ($m), 2017–26
Table 99: Invega Sustenna/Invega Trinza drug profile
Table 100: Invega Sustenna pivotal trial data in schizophrenia
Table 101: Invega Trinza pivotal trial data in schizophrenia
Table 102: Invega Sustenna sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 103: Invega Trinza sales for schizophrenia across the US and five major EU markets, by country ($m), 2017–26
Table 104: Latuda drug profile
Table 105: Latuda pivotal trial data in schizophrenia
Table 106: Latuda other late-phase trial data in schizophrenia
Table 107: Latuda sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country ($m), 2017–26
Table 108: Lonasen drug profile
Table 109: Lonasen pivotal trial data in schizophrenia
Table 110: Lonasen transdermal patch trial data in schizophrenia
Table 111: Lonasen ongoing trials in schizophrenia
Table 112: Lonasen sales for schizophrenia in Japan ($m), 2017–26
Table 113: Rexulti drug profile
Table 114: Rexulti pivotal trial data in schizophrenia
Table 115: Rexulti sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 116: Risperdal Consta drug profile
Table 117: Risperdal Consta pivotal trial data in schizophrenia
Table 118: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 119: Saphris drug profile
Table 120: Saphris pivotal trial data in schizophrenia
Table 121: Saphris sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country ($m), 2017–26
Table 122: Seroquel/Seroquel XR drug profile
Table 123: Seroquel/Seroquel XR pivotal trial data in schizophrenia
Table 124: Seroquel/Seroquel XR sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 125: Vraylar drug profile
Table 126: Vraylar pivotal trial data in schizophrenia
Table 127: Vraylar other late-phase trial data in schizophrenia
Table 128: Vraylar sales for schizophrenia across the US and five major EU markets, by country ($m), 2017–26
Table 129: Zyprexa drug profile
Table 130: Zyprexa pivotal trial data in schizophrenia
Table 131: Zyprexa sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 132: Profiled pipeline products in development for schizophrenia
Table 133: ALKS 3831 drug profile
Table 134: ALKS 3831 Phase III data in schizophrenia
Table 135: ALKS 3831 Phase III trials in schizophrenia
Table 136: ALKS 3831 sales for schizophrenia in the US ($m), 2017–26
Table 137: Lu AF35700 drug profile
Table 138: Lu AF35700 Phase II and Phase III trials in schizophrenia
Table 139: MIN-101 drug profile
Table 140: MIN-101 planned Phase III trial in schizophrenia
Table 141: MIN-101 Phase IIb trial data in schizophrenia
Table 142: MIN-101 sales for schizophrenia in the US ($m), 2017–26
Table 143: Nuplazid drug profile
Table 144: Nuplazid Phase II and Phase III trials in schizophrenia
Table 145: Nuplazid Phase II data in schizophrenia
Table 146: Nuplazid sales for schizophrenia across the US and five major EU markets, by country ($m), 2017–26
Table 147: Lumateperone drug profile
Table 148: Lumateperone Phase II and Phase III data in schizophrenia
Table 149: Lumateperone other interim Phase II data in schizophrenia
Table 150: Lumateperone sales for schizophrenia in the US ($m), 2017–26
